A detailed history of Entry Point Capital, LLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 52,760 shares of XERS stock, worth $189,408. This represents 0.08% of its overall portfolio holdings.

Number of Shares
52,760
Previous 34,633 52.34%
Holding current value
$189,408
Previous $98,000 81.63%
% of portfolio
0.08%
Previous 0.06%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$2.78 - $3.73 $50,393 - $67,613
18,127 Added 52.34%
52,760 $178,000
Q3 2024

Nov 13, 2024

BUY
$2.06 - $2.96 $71,343 - $102,513
34,633 New
34,633 $98,000
Q1 2024

May 14, 2024

BUY
$2.04 - $3.22 $8,084 - $12,760
3,963 New
3,963 $8.76 Million

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $488M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Entry Point Capital, LLC Portfolio

Follow Entry Point Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Entry Point Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Entry Point Capital, LLC with notifications on news.